The Semaglutide Treatment Effect in People with obesity (STEP) program aims to investigate the effect of semaglutide versus placebo on weight loss, safety, and tolerability in adults with obesity or overweight.

These trials and studies were funded by Novo Nordisk and was the basis of the FDA's approval for semaglutides use for weight loss.

STEP 1 - https://pubmed.ncbi.nlm.nih.gov/35441470/
https://clinicaltrials.gov/ct2/show/results/NCT03548935?view=results
Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.

STEP 2 - https://pubmed.ncbi.nlm.nih.gov/33667417/
Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomized, double-blind, double-dummy, placebo-controlled, phase 3 trial.

STEP 3 - https://pubmed.ncbi.nlm.nih.gov/33625476/
Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial.

STEP 4 - https://pubmed.ncbi.nlm.nih.gov/33755728/
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.

STEP 5 - https://pubmed.ncbi.nlm.nih.gov/36216945/
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial.

STEP 6 - https://pubmed.ncbi.nlm.nih.gov/35131037/
Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial.

STEP 7 - ?

STEP 8 - https://pubmed.ncbi.nlm.nih.gov/35015037/
Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.

Other/Related

Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5
https://pubmed.ncbi.nlm.nih.gov/32441473/